Double click on our CAPAC technology! We’re excited to unveil our new animation, describing how our CAPAC technology is transforming tumor targeted drug activation. For more info check out www.shasqi.com/our-science #oncology #clickchemistry #innovation #cancer
Shasqi
Biotechnology Research
San Francisco, California 2,225 followers
Targeting cancer with click chemistry
About us
Shasqi is a biotech company whose mission is to revolutionize cancer treatment with click chemistry, a 2022 Nobel Prize winning technology. Our unique CAPAC® (Click Activated Protodrugs Against Cancer) platform uses click chemistry to target high doses of cancer drugs directly to the site of the tumor while minimizing toxicity to healthy cells, potentially improving the therapeutic index. Shasqi has developed an expansive and diverse library of antibody-mediated tumor-targeting agents and cancer therapeutic payloads. These are decoupled from each other and reunited at the site of the tumor via a click chemistry reaction. We are the first company to use click chemistry in humans. For more information, visit us at www.shasqi.com
- Website
-
https://www.shasqi.com
External link for Shasqi
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, California
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Oncology and Click Chemistry
Locations
-
Primary
Get directions
San Francisco, California 94107, US
Employees at Shasqi
Updates
-
The countdown has started ⏱ Our team will be traveling to Boston in September! Shasqi’s VP of Research, Travis Biechele will be speaking at the ADC & Radiopharmaceutical Pharma & Biotech Partner Summit on September 9th Join him to talk next-generation targeted therapies 👉 https://lnkd.in/gQPMGsJz #ADC #innovation #biotech #pharma #radiopharmaceuticals
-
-
The Shasqi team are not only brilliant scientists, they are also artists, gardeners, apiarists, and surfers. Check us out! 1) Sadie is super creative - she made this 👇 3D artwork representing Elton John’s 1970s appearance on the Muppets! 2) Tri-Hung recently took up beekeeping and built his own beehive! 3) Stefanie gets creative with her vegetable garden and grew a unique, curly cucumber. 4) José likes to hang ten on the waves of the Bay Area. #WhenItClicks #team
-
-
We’re excited to celebrate Brad Juzkow's 3-year anniversary at Shasqi! Brad, your hard work and attention to detail have made a significant difference to our team. We truly appreciate your contributions and the positive energy you bring every day. Will you be getting a new tattoo to celebrate??? Here’s to continuing this great work together! #workanniversary
-
-
Wow! Honored to be included by Christopher Merrett as part of the University of Nottingham Summer School of Pharmacy curriculum. Congrats Emmanuella Fernandez on completing your course. #biorthogonalchemistry
☀️SUMMER SCHOOL COMPLETED!!☀️ I’m excited to share my recent experience at the University of Nottingham Summer School for Pharmacy! Here are some of my highlights: ☀️Monday FIRST ACADEMIC SESSION!! - Introduction to the MPharm Degree We discussed: • Skills of a good Pharmacist • The MPharm Course Structure • Career Trajectory (MPharm degree; Foundation Training; Pharmacist Career) Patient Case Study: • Introduced to ‘WWHAM’ questioning technique & non-pharmacological management: the management of pain without medications • Analysed a case study of a constipated pregnant woman & discussed suitable management/medicines ☀️Tuesday ‘Biopharmaceutics: Believing, Buying & Bias’ with Catherine Vanessa Finch: A lecture focused on the misinformation of Nurofen’s Express line: though products are identical both pharmacologically (their actions, use & effect on the body) & in terms of pharmaceutics (the formulations of the drug & how this relates to their function) they are inaccurately advertised as able to target specific pain sites Tabletting Practical with John Korwin Granford: This practical allowed us to begin considering the criteria required for tablets to be both transportable & effective for use. We tested our tablet samples for: • Uniformity Of Weight - What’s the acceptable range for the tablets’? • Friability - How durable are the tablets? • Hardness Of Formulations - What’s are the tablets’ ‘breaking points’? • Disintegration Time - How fast would the tablets dissolve under the body’s conditions? ☀️Wednesday Degradation Of Aspirin Practical with Christopher Merrett & John Korwin Granford: • Determined the absorption of known concentrations of salicylic acid, using the Beer-Lambert Law to plot a calibration curve. We concluded that the greater the concentration of salicylic acid, the higher the absorption • Determined the mass of salicylic acid in unknown samples, testing both our analytical & mathematical skills ☀️Thursday Bioorthogonality & Targeted Therapeutics with Christopher Merrett: • A fascinating lecture which revealed to us the existence of bioorthogonal chemistry - any chemical reaction that can occur inside of living systems without interfering with native biochemical processes • Discussed therapeutic uses of bioorthogonal chemistry - companies like Shasqi are researching platforms which would use bioorthogonal ‘click chemistry’ for targeted cancer treatments, enabling the activation of powerful cancer drugs at tumour sites Pharmacy Q&A: • Spoke to university lecturers & researchers about their academic/career trajectories • I personally gained a greater understanding of where a degree in Pharmacy could take me - from PhD research to a career with Mars Inc.!! Overall, this Summer School was an invaluable experience, providing me with incredible knowledge into a multitude of things concerning the pharmaceutical industry. I look forward to seeing where this knowledge will take me, and updating you guys along my journey!!
-
-
-
-
-
+9
-
-
DYK Shasqi's CAPAC technology can be used to localize RLTs ⚡ to the tumor? A major pain point for mAb-based radioconjugates is the prolonged exposure and low tumor-to-blood ratio, which causes dose-limiting toxicities. To overcome this, Shasqi separates the radionuclide from the targeting component and reunites the two at the tumor using click chemistry. This enables optimal clearance of the RLT and reduces non-specific toxicities. Shasqi's Jesse McFarland and Tri-Hung Nguyen recently presented a poster on this apprpach at the Gordon Research Conferences, 'Exploring the Power of Radioimmunobiology Via Switching the Radionuclides, Ligands and Immunotargets' in beautiful Maine. Learn more: https://bit.ly/46lz190 #RLTs
I recently had the pleasure of attending the Gordon Research Conference on Targeted Radionuclides in Oncology with my colleague, Tri-Hung Nguyen. It was exciting to hear recent developments in the field of radioligand therapies (RLTs) and experience the discussions on key topics for the discovery of next gen therapeutics, including choice of radionuclide and targeting modality. While RLTs clearly have the potential to deliver powerful anti-tumor efficacy to patients, the burning question on everyone's mind is how the toxicities can be derisked through preclinical and Phase 0 studies, including biodistribution and ADME analysis. The future of RLTs is bright!
-
Exciting News! Shasqi’s VP of Research, Travis Biechele will be sharing our latest data at the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit on September 9th in Boston. Learn more 👇 #hansonwade #ADCs #BD
-
Shasqi Directors, Jesse McFarland, Director of Chemistry & Bioconjugates and Tri-Hung Nguyen, Senior Director of Translational Sciences, are heading to the Radionuclide Theranostics for the Management of Cancer Gordon Research Conference (GRC) next week. They will be presenting data on how systemic toxicities associated with RLTs can be overcome using our CAPAC technology. Historically, it has been challenging to target RLTs to the tumor using monoclonal antibody-based radioconjugates, due to dose limiting toxicities based on extended systemic exposure and low tumor-to-blood ratio. Our CAPAC platform separates the chelation from the antigen-binding moiety and uses small format binders. This improves on-tumor payload activation and reduces normal tissue exposure, enabling optimal RLT clearance and reducing non-specific toxicity. If you'll be at GRC, stop by our poster to say hi. #RLTs #targetedtherapy #gordonresearchconferences
-
-
Only 1% of an ADC dose reaches the tumor, with 99% eliminated by normal tissues, contributing to toxicity that limits efficacy. How do we solve this to maximize the therapeutic index of powerful cancer drugs? Separation of tumor targeting from payload! We infuse an antigen binder activator that does not carry payload, then we infuse an inert protodrug, which finds the activator at the tumor and, Click! A click chemistry reaction occurs on the surface of the cell, releasing the active payload at the tumor. In addition to limiting exposure to normal tissues, the separation of components also allows us to find the optimal activator to protodrug ratio. Find out more in this clip from our animation and click below to watch the full video. www.shasqi.com/our-science #oncology #innovation #ADCs
-
To celebrate Sangeetha Srinivasan's 7-year anniversary, here are 7 reasons why we’re privileged to have Dr. Srinivasan on the Shasqi team. 1. Thoughtful people manager with high EQ 2. Excellent problem solver 3. Highly strategic 4. Takes the initiative and steps up to lead 5. Committed advocate for equality in the workplace 6. Passionate about improving the lives of cancer patients 7. And last, but not least, a talented singer of Indian Carnatic Music! 🎶 We may not say it enough, but thank you for everything you do!
-